10-Q: Guardant Health Reports Strong Revenue Growth Driven by Shield Launch and Oncology Test Volume, Reduces Net Loss Amidst Strategic Investments and Legal Victories

Guardant Health, a precision oncology company, reported significant revenue increases for Q2 and H1 2025, driven by the commercial launch of its Shield colorectal cancer screening test and growth in oncology test volumes, while also reducing its net loss despite increased operating expenses and navigating complex legal proceedings.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 31% to $232.1 million, up from $177.2 million in the prior year period.
• Oncology revenue grew 22% to $158.7 million, driven by a 30% increase in oncology test volume to approximately 64,000 tests.
• Biopharma and data revenue increased 28% to $56.0 million, due to higher test volumes and average selling prices for GuardantINFINITY, and growth in service agreements.
• Screening revenue, primarily from the Shield test, generated $14.8 million from approximately 16,000 tests in Q2 2025, a new revenue stream.
• Net loss for the three months ended June 30, 2025, was $(99.9) million, an improvement from $(102.6) million in the same period last year.
• For the six months ended June 30, 2025, total revenue increased 26% to $435.6 million, and net loss improved to $(195.1) million from $(217.6) million.
• Operating expenses increased across all categories, with sales and marketing up 46% to $119.6 million in Q2 2025, reflecting commercial team expansion and marketing for the Shield launch.
• Cash, cash equivalents, and restricted cash stood at $735.5 million as of June 30, 2025.
• A $13.7 million gain on extinguishment of convertible notes was recognized in the six months ended June 30, 2025, following a note exchange transaction.
• The company secured a significant legal victory against Natera, Inc., with a jury awarding $292.5 million in damages, including $175.5 million in punitive damages, for false advertising and unfair competition, which was affirmed at $287.0 million post-trial.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, significant product milestones (Shield FDA approval, NCCN inclusion, Medicare/VA coverage), and a major legal win against Natera. However, this is tempered by continued net losses, increased operating expenses, and ongoing, complex patent infringement lawsuits that present future financial and operational risks.

Positives

• Strong revenue growth of 31% quarter-over-quarter and 26% year-to-date, indicating increasing market adoption of products.
• Significant increase in oncology test volume (30% Q-o-Q) and improved reimbursement for Guardant360 CDx and Guardant360 Liquid tests.
• Successful commercial launch and initial revenue generation from the Shield colorectal cancer screening test.
• FDA approval of the Shield blood test for primary colorectal cancer screening in adults aged 45 and older, enhancing market credibility and access.
• Inclusion of the Shield blood test in National Comprehensive Cancer Network (NCCN) updated colorectal cancer screening guidelines, supporting broader clinical adoption.
• Medicare coverage for the Shield blood test and ADLT status approval by CMS, facilitating reimbursement.
• VA network coverage for the Shield blood test for individuals aged 45-64, expanding access beyond Medicare beneficiaries.
• FDA Breakthrough Device designation granted to the Shield multi-cancer detection (MCD) test, accelerating its development and review.
• Expanded Medicare coverage for Guardant Reveal (colorectal cancer recurrence monitoring) and Guardant360 Tissue (DNA and RNA testing).
• Recognition of a $13.7 million gain on extinguishment of convertible notes from the February 2025 exchange transaction.
• Substantial legal victory against Natera, Inc., with a jury award of $292.5 million (affirmed at $287.0 million), including punitive damages, for false advertising and unfair competition.
• Net loss decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, despite increased operating expenses.

Negatives

• Continued net losses of $(99.9) million for Q2 2025 and $(195.1) million for H1 2025, indicating ongoing unprofitability.
• Increased operating expenses across all categories, particularly sales and marketing (up 46% Q-o-Q), reflecting high investment in growth.
• Interest income decreased by 46% Q-o-Q due to reduced investment balances and lower market rates.
• Stockholders deficit increased to $(305.5) million as of June 30, 2025, from $(139.6) million at December 31, 2024.
• Cash used in financing activities for H1 2025 amounted to $(65.2) million, primarily due to treasury stock repurchases and debt issuance costs.
• Ongoing patent infringement lawsuits with TwinStrand Biosciences/University of Washington, Tempus AI, Inc., and Cold Spring Harbor Laboratory, posing potential financial liabilities and operational constraints.
• A jury verdict in November 2023 found willful infringement against the company in the TwinStrand Biosciences case, resulting in an $83.4 million damages award and ongoing legal contestation.

Risks

• Uncertainty and unpredictability of payer coverage and reimbursement for tests, which can significantly impact revenue recognition and cash collections.
• Potential for future revenue reversal if actual cash collections differ from estimated variable consideration, especially with non-contracted payers.
• Changes to Current Procedural Terminology (CPT) coding or Z-Code Identifiers could reduce, hold, or eliminate payments for certain test uses.
• Significant investment in research and development, including clinical studies, which may not yield desired product development or market adoption outcomes.
• Challenges in international expansion due to internal and external constraints, global economic conditions, and geopolitical tensions (e.g., U.S.-China bilateral relationship impacting partnerships in China).
• Fluctuations in sales and marketing expense, and general and administrative expense, which can impact financial results.
• Ongoing legal proceedings, including patent infringement suits (TwinStrand Biosciences, Tempus AI, Cold Spring Harbor Laboratory) and wage and hour class action lawsuits, which could result in substantial payments, injunctions, or changes to business operations.
• The $83.4 million jury verdict in the TwinStrand Biosciences patent infringement case, which is being vigorously contested but remains a significant potential liability.
• Exposure to market risk from changes in interest rates affecting cash, cash equivalents, restricted cash, and indebtedness.
• Exposure to foreign currency risk as international operations expand, which could adversely affect results of operations and cash flows.

Future Outlook

The company expects continued increases in operating expenses due to investments in clinical studies, new product development, sales organization expansion, and marketing efforts. It anticipates that the cost per test will modestly decrease over time due to efficiencies from increased test volume and automation. The company also expects to expand into lung cancer screening and multi-cancer detection with its Shield platform and continue to grow its international commercial footprint. Management believes current cash and anticipated cash flows will be sufficient to meet cash requirements for more than 12 months.

Management Comments

• We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.
• We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, and real-world data.
• Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
• We have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation.
• The success of our international expansion strategy depends on a number of factors, including the internal and external constraints placed on our international laboratory partners and biopharmaceutical companies in the context of broader global, regional and U.S. economic and geopolitical conditions.
• We strongly disagree with the jury verdict in the TwinStrand Biosciences case and will vigorously contest the verdict and judgment through post-trial motions and, if needed, through appeal.

Industry Context

Guardant Health operates in the rapidly evolving precision oncology and liquid biopsy market. The FDA approval and NCCN inclusion of its Shield test for colorectal cancer screening position it as a leader in early cancer detection, a significant growth area. The company's continued investment in R&D for multi-cancer detection and lung cancer screening aligns with broader industry trends towards less invasive, earlier diagnostic tools. Its partnerships with biopharmaceutical companies and international expansion efforts reflect the global nature of cancer research and treatment development. The legal challenges, particularly patent disputes, are common in the highly competitive and innovative diagnostics industry, where intellectual property is a key asset.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The focus is on the company's internal performance and product milestones.

Legal Proceedings

• TwinStrand Biosciences, Inc. and University of Washington vs. Guardant Health, Inc.: Patent infringement suit filed in August 2021. Jury found willful infringement of U.S. Patent Nos. 10,287,631 and 10,760,127 on November 14, 2023, awarding $83.4 million in damages. The company is vigorously contesting the verdict and judgment through post-trial motions and potential appeal. $105.7 million in restricted cash is held as collateral for surety bond requirements related to this dispute.
• Guardant Health, Inc. v. Tempus AI, Inc.: Company filed a patent infringement suit on June 11, 2024, alleging infringement of U.S. Patent Nos. 11,149,306; 9,902,992; 10,501,810; 10,793,916; and 11,643,693. Tempus moved to dismiss in October 2024. Trial is set for May 2027.
• Tempus AI, Inc. v. Guardant Health, Inc.: Tempus filed a patent infringement lawsuit on March 14, 2025, alleging infringement of U.S. Patent Nos. 10,957,041; 10,991,097; 11,640,859; and 12,112,839. The company filed a motion to dismiss and transfer the case on May 5, 2025, with a hearing set for July 31, 2025.
• Cold Spring Harbor Laboratory v. Guardant Health, Inc.: CSHL filed a patent infringement lawsuit on March 6, 2025, alleging infringement of U.S. Patent No. 10,947,589 by Guardant360. The company filed a motion to dismiss on May 28, 2025. Trial is set for April 19, 2027.
• Guardant Health, Inc. v. Natera, Inc.: Company filed a false advertising lawsuit in May 2021. A jury found in favor of the company on November 25, 2024, awarding $292.5 million, including $175.5 million in punitive damages, and rejected Natera's counterclaims. Post-trial motions resulted in the affirmation of a $287.0 million total damages award and an award of approximately $3 million in attorneys' fees to the company.
• Wage and Hour Class Action Lawsuits: The company is a defendant in two class action lawsuits in California Superior Courts alleging violations of the California Labor Code, including claims for unpaid wages, overtime, and meal/rest period violations. One lawsuit also alleges an unlawful post-employment non-compete clause. The company denies the allegations, and the cases are in early stages with class certification not yet granted.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, new product approvals, and a significant legal win. However, continued net losses and ongoing legal liabilities could impact profitability and share price. The At-The-Market offering could lead to dilution if shares are sold.
• Customers (Patients & Healthcare Providers): Benefit from expanded access to advanced cancer diagnostic and screening tests (Shield, Guardant Reveal, Guardant360 Tissue) through FDA approvals, Medicare, and VA coverage.
• Biopharmaceutical Companies: Continued collaboration and service agreements, including GuardantINFINITY and GuardantINFORM, support drug development and research.
• Employees: Stock-based compensation is a significant component of compensation, intended to incentivize and retain talent. Workforce reductions mentioned under G&A expense could impact some employees, though specific details are not provided.
• Creditors (Convertible Note Holders): The convertible note exchange transaction restructured debt, potentially impacting future interest payments and conversion terms.

Next Steps

• Continue investment in research and development to innovate and develop additional products, including expanding genomic and medical data management resources.
• Conduct ongoing and new clinical studies, such as the SHIELD LUNG study and participation in the NCI's Vanguard study for multi-cancer detection.
• Expand commercial footprint internationally, building on existing partnerships in Asia, the Middle East, Africa, Japan, Europe, and China.
• Vigorously contest the jury verdict and judgment in the TwinStrand Biosciences patent infringement lawsuit through post-trial motions and potential appeal.
• Continue to defend against patent infringement lawsuits filed by Tempus AI, Inc. and Cold Spring Harbor Laboratory.
• Address wage and hour class action lawsuits, including potential class certification and discovery phases.
• Potentially raise additional capital through the At-The-Market Offering Program or other financing opportunities to support business expansion and strategic investments.

Key Dates

Recommendation

Guardant Health demonstrates strong operational momentum with significant revenue growth driven by its core oncology tests and the successful commercial launch of the Shield colorectal cancer screening test, which has achieved key regulatory and reimbursement milestones. The substantial legal victory against Natera provides a significant financial boost. However, the company continues to incur considerable net losses due to aggressive investments in R&D and sales & marketing, and faces multiple ongoing patent infringement lawsuits that present material financial and operational uncertainties. While the long-term potential in precision oncology and early cancer detection is compelling, the current financial losses and legal overhang warrant a 'Hold' recommendation, advising investors to monitor progress on profitability and legal resolutions before making further commitments.

Keywords

Precision Oncology, Liquid Biopsy, Cancer Screening, Colorectal Cancer, Lung Cancer, Multi-Cancer Detection, Guardant360, Guardant Reveal, Shield Test, FDA Approval, Medicare Coverage, Biopharma Partnerships, Clinical Studies, Intellectual Property, Patent Infringement, False Advertising, Convertible Notes, Financial Results, Diagnostics, Genomic Profiling